Fenofibrate research for the treatment of COVID-19.

Not Applicable

Recruiting

• Conditions: -B338 Other specified viral diseases; Other specified viral diseases; B338

• Registration Number: PER-099-20
• Lead Sponsor: IVERSIDAD CATOLICA DE SANTA MARIA,

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-12-30
• Study Completion: 2022-02-03
• Last Update Posted: 4 September 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 115

Inclusion Criteria

1. Age 18 years or older.
2. Diagnosis of COVID-19 (of any severity), based on: (a) A clinical presentation consistent with a positive laboratory test for SARS-CoV-2 (serological test or PCR); or (b) Considered by the family medical team as a person under investigation who is undergoing laboratory tests for COVID-19, with high clinical probability, in addition to compatible pulmonary infiltrates in radiographic plaque or chest tomography (bilateral, interstitial or ground glass opacities). Inclusion will require meeting criterion (2a) only, criterion (2b) only, or both. Patients who do not have a typical acute symptomatic picture of COVID-19 should not be included.
3. Ability to give informed consent.
4. Less than 14

Exclusion Criteria

1. Known pregnancy or lactation.
2. Estimated glomerular filtration rate (eGFR) 60 mL/min/1.73m2 or on dialysis (chronic renal disease stage 3-5).
3. History of active liver disease, cholelithiasis, hypothyroidism or rhabdomyolysis (suspected or confirmed). For purposes of the study, any history of chronic hepatopathy (including chronic hepatitis of any etiology, liver cirrhosis), recent history (last 12 months) of acute hepatitis of any etiology shall be considered as active liver disease, or in the context of COVID-19, increase in circulating AST or ALT >3 times the upper normal limit (to be performed on all patients at trial cost, unless already available in the patient within the last 72 hours). Fatty liver without hepatitis, or a remote history (>12 months) of acute viral (e.g., hepatitis A) or medication-induced hepatitis that has not progressed to chronic liver disease, do not constitute an exclusion criterion for the study.
4. Known hypersensitivity to fenofibrate or fenofibric acid.
5. Current treatment with fenofibrate, clofibrate, warfarin or other coumarinic anticoagulants, glimepiride, cyclosporine, tacrolimus.
6. Use of statins, except simvastatin or atorvastatin. For these 2 statins, patients taking doses >40 mg/day will be excluded.
8. Inability to read, write, or lack of access to a phone.
9. Patients with endotracheal intubation.

Study & Design

• Study Type: Interventional
• Study Design: Not specified